| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Phil | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $119.43MM | Series D | 7/3/2021 | $61.34MM | $321.12MM | $4.06 | Warburg Pincus | ||||
 | PROCEPT BioRobotics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $341.8MM | Series G | 6/30/2021 | $85MM | $872.62MM | $4.02 | Fidelity, T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors LP, Duquesne Family Office | ||||
 | Science Corporation | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $494.02MM | Series C | 3/5/2026 | $230.05MM | $1.5B | $8.36 | Khosla Ventures, Lightspeed Venture Partners, Y Combinator, In-Q-Tel, Quiet Capital, Mangusta Capital, Octant Ventures, RRE Ventures | ||||
 | Secretome Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Skyhawk Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Soda Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Somatus | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.41B | Series Junior-2NV | 6/27/2025 | $300MM | $4.98B | $1,320.56 | Undisclosed Investors | ||||
 | Star Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
| Syntis Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Thrive Global | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $183.21MM | Series C-1 | 7/8/2021 | $80MM | $724.52MM | $3.39 | Kleiner Perkins, Owl Ventures, Jazz venture Partners, Institutional Venture Partners, Goldman Sachs Asset Management | ||||
 | Truepill | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $929.28MM | Series E-1 | 8/16/2023 | $7.49MM | $541.17MM | $22.68 | Undisclosed Investors | ||||
 | Unite Us | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $249.49MM | Series C-2 | 10/27/2021 | $34.77MM | $2.05B | $248.39 | ICONIQ Capital, Optum Ventures, Salesforce Ventures | ||||
 | Vets First Choice | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Xalud Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $72.64MM | Series C | 8/24/2021 | $32.75MM | $259.4MM | $2.80 | PBM Capital Group | ||||
 | Xynomic Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | ZnanyLekarz | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Abpro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $69.53MM | Series F | 3/30/2022 | $2MM | $628.78MM | $18.00 | Undisclosed Investors | ||||
 | Adicet Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Aiolos Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $247.55MM | Series A | 10/24/2023 | $180MM | $436.12MM | $1.19 | Atlas Venture, Bain Capital Life Sciences, Forbion, Sofinnova Investments, RA Capital Management | ||||
 | Ambros Therapeutics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $154.72MM | Series A-1 | 9/30/2025 | $125.43MM | $244.62MM | $4.70 | Undisclosed Investors | ||||
 | Ampersand Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $109.61MM | Series B | 3/19/2025 | $65MM | $360.94MM | $5.80 | Flagship Pioneering, Eli Lilly & Company | ||||
 | Archy | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Areteia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $360MM | Series A-1 | 2/21/2025 | $180MM | $1.13B | $10.00 | Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace | ||||
 | Arrakis Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||